Leave Your Message
products-news-banners02

FDF

Our self-developed drug has been approved for market by multiple countries, with over 30 ongoing research projects

    Semaglutide Injection
    con-1
    01

    Semaglutide Injection
    Diabetes Mellitus
    Teriparatide Injection
    con-1
    02

    Teriparatide Injection
    Osteoporosis
    FirstPrev123NextLastTotal 3

    Product Pipeline

    R&D Projects Indications Status
    HY3000 Nasal Spray Prevention & treatment of COVID-19 Phase III
    HY3001 COVID-19 Peptide Vaccine Prevention of COVID-19 Preclinical
    HY3003 GLP-1R/GIPR/GCGR Triple Agonist Diabetes mellitus & Weight loss & MASH Preclinical
    Glatiramer Acetate Injection Multiple sclerosis Approved in US
    Cetrorelix Acetate for Injection Assisted reproduction Pending approval
    Teriparatide Injection Osteoporosis  Pending approval
    Carboprost Tromethamine Injection Postpartum hemorrhage Pending approval
    Semaglutide Injection Diabetes mellitus & Weight loss Phase III
    Abaloparatide Injection Osteoporosis FDF Process Validation
    Teriparatide Acetate for Injection Osteoporosis  FDF Process Validation
    Difelikefalin acetate Injection CKD-Pruritus FDF Process Validation
    Tirzepatide Injection Diabetes mellitus & Weight loss FDF Process Validation
    Linaclotide Capsules IBS-C and CIC FDF Process Validation
    Plecanatide Tablets IBS-C and CIC API Process Validation
    Etelcalcetide Hydrochloride Injection CKD-Econdary hyperparathyroidism API Process Validation
    Lanreotide Acetate Sustained-Release Injection Acromegaly API Process Validation
    Semaglutide Tablets Diabetes mellitus & Weight loss API Process Validation
    Sucrose Iron Hydroxide Chewable Tablets CKD-Related hyperphosphatemia R&D
    Ferric Carboxymaltose Injection Iron deficiency anemia R&D
    Pegcetacoplan Injection Geographic atrophy R&D